FindTrial
Sign In

Adverse events frequency caused by nivolumab and ipilimumab combination therapy: meta-analysis

Adverse events frequency caused by nivolumab and ipilimumab combination therapy: meta-analysis - Adverse events frequency caused by nivolumab and ipilimumab combination therapy: meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000044090
Enrollment
Unknown
Registered
2021-05-01
Start date
2021-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancers

Interventions

None listed

Sponsors

Yokohama City University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Cancer type is not questioned since safety profile is not largely affected by cancer type as long as the same regimen was selected. Patients should not be previously treated by any anti-cancer medications such as cytotoxic drugs, molecular targeted therapy, and ICIs. No restriction is set for performance status and age.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Per-person frequencies of any AE (any grade, Grade 3 or higher(G3-)), serious AE (any grade, Grade 3 or higher), AE discontinuation (any grade, Grade 3 or higher), treatment-related death.—

Countries

Japan

Contacts

Public ContactNobuyuki Horita

Yokohama City University Hospital Chemotherapy Center

horitano@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026